AMR is threatening human and animal health as well as the environment. The consequences of inaction are too grave to contemplate.
The Pharmaceutical Strategy is a chance to tackle antimicrobial resistance that Europe cannot miss says the MEP Interest Group on AMR
Members of the European Parliament from the MEP Interest Group on AMR and supporting MEPs call on the European Commission to ensure the proposed Pharmaceutical Strategy includes strong measures to tackle antimicrobial resistance
EPHA has joined with other health and environmental organisations calling for the development of a strong legislative framework to increase transparency throughout the entire pharmaceutical supply chain.
About the AMR Stakeholder Network
Analysis & Opinion
A report on the third online discussions organised by the MEP Interest Group on AMR the development of new needs-driven models to finance and stimulate antibiotic R&D could be supported and how the EU could promote R&D models that ensure responsible use of and equitable and affordable access to antibiotics.
A report on the second of the online discussions organised by the MEP Interest Group on AMR on what measures can be taken to reduce the use of antimicrobials in agriculture
Get the monthly EPHA AMR Feed!
MEP Interest Group on AMR 2020 Webinar Series
13,16,17 November 2020
AMR: setting the agenda for change Official launch of the MEP Interest Group on AMR
19 February 2020
Invest and Protect
7 May 2019
Joining the Dots
30 January 2018
Do you have a question?
Meet our AMR Policy Leads and Scientific Advisors
Rose Gallagher MBE
EPHA Scientific Advisor on AMR
Professional Lead Infection Prevention & Control, Royal College of Nursing (UK)